ArticleJournal of applied clinical medical physics2025
Integrating multiparametric MRI radiomics and clinical models to assess sensitivity to neoadjuvant chemotherapy in breast cancer: A multicenter study.
Article in Journal of applied clinical medical physics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Simultaneous Preoperative Prediction of Locally Advanced Breast Cancer, DCIS Component, and Multifocality Using Structured Mammographic Features and Gradient-Boosting Machine Learning.Diagnostics (Basel, Switzerland) · 2026Article
- Integrating multiparametric MRI radiomics and clinical models to assess sensitivity to neoadjuvant chemotherapy in breast cancer: A multicenter study.Journal of applied clinical medical physics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo develop and externally validate an interpretable multiparametric MRI-based radiomic-clinical model using Shapley Additive Explanations (SHAP) methodology for early prediction of breast cancer sensitivity to neoadjuvant chemotherapy (NAC).
methodsThis retrospective multicentric study enrolled 223 breast cancer patients from three medical centers. Patients underwent pretreatment multiparametric MRI (DCE-MRI and DWI sequences) with Miller-Payne grades 4-5 defining NAC-sensitive. Manual tumor segmentation generated regions of interest for extracting 2,396 radiomic features per patient. Feature selection integrated reproducibility analysis (ICC > 0.7), univariable significance testing (p < 0.01), LASSO regression, and hierarchical clustering. A support vector machine (SVM) model incorporated optimized radiomic signatures and clinical variables. SHAP methodology provided global feature importance interpretation and individualized prediction explanations.
resultsThe integrated radiomic-clinical model demonstrated superior performance to standalone clinical (AUC 0.720) and radiomic (AUC 0.833) models in the internal validation set, achieving an AUC of 0.904 (95% CI: 0.816-0.991). This advantage persisted in external validation (AUC 0.928, 95% CI: 0.874-0.982). SHAP analysis identified wavelet_HHL_glcm_Correlation_DCE as the predominant predictive feature, with high values significantly correlating to NAC-sensitive. A clinical nomogram translated model outputs into quantifiable risk probabilities, where total scores ≥130 indicated > 95% sensitivity likelihood.
conclusionThe SHAP-explainable radiomic-clinical model provides a clinically applicable, noninvasive tool for pretreatment stratification of NAC sensitivity. This approach enhances personalized therapeutic decision-making while minimizing unnecessary treatment toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.